Latest Breaking News On - University of lausanne fadi fakhouri - Page 1 : comparemela.com

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

United statesFadi fakhouriCaroline baumalEuropean renal association congressUniversity of lausanne fadi fakhouriApellis pharmaceuticals incLausanne university hospitalAmerican society of nephrology kidney weekLausanne universityAmerican societyNephrology kidney weekEuropean renal associationApellis pharmaceuticals